Bioequivalence Study of Linagliptin 5 mg Tablets in Healthy Volunteers Under Fasting Conditions for Diabetes Management

The primary objective of this study is to evaluate the **bioequivalence** of linagliptin 5 mg film-coated tablets when administered as a single oral dose to healthy volunteers under fasting conditions. This is clinically relevant as establishing bioequivalence ensures that the generic formulation of linagliptin is therapeutically equivalent to the reference product, which is crucial for maintaining consistent efficacy and safety in the management of **diabetes**. No secondary objectives are provided in the available data.

The clinical trial involves participants diagnosed with **diabetes**. The study population includes both male and female subjects, with an age range category code of 3, which typically corresponds to adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or the selection process for the trial population. Additionally, there is no data available on lifestyle considerations such as diet, physical activity, or habits. The sponsor has not disclosed any key inclusion or exclusion criteria for this study.

The clinical trial is designed as a **randomized**, crossover bioequivalence study to evaluate the pharmacokinetic properties of linagliptin 5 mg film-coated tablets. The trial involves a single oral dose administration to healthy volunteers under fasting conditions. The study is conducted in a **double-blind** manner to ensure unbiased results. The trial is categorized as a Phase 2 study, focusing on the treatment of **diabetes**. The estimated recruitment start date is July 3, 2023, with an anticipated end date of August 2, 2023, indicating a total trial duration of approximately one month.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive the investigational product. The study includes multiple follow-up visits to monitor safety and collect pharmacokinetic data. The end-of-study visit will conclude the trial, where final assessments will be conducted to ensure participant safety and gather any remaining data. The expected length of participant involvement is approximately one month, aligning with the overall trial duration. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it has been designated as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the provided data, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be elaborated upon. The trial documentation should be consulted for comprehensive information regarding the treatments involved in this clinical trial.

The clinical trial is in Phase 2, focusing on evaluating the efficacy of the investigational treatment. The trial is scheduled to commence recruitment on July 3, 2023, with an estimated end date of August 2, 2023. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy measurement are not detailed in the available data. The trial will adhere to standard protocols for data collection and analysis, ensuring that the results are scientifically valid and reliable. The trial's design and execution will follow rigorous clinical standards to assess the treatment's impact accurately.